Beta Bionics (NASDAQ:BBNX) Insider Mike Mensinger Sells 2,200 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 2,200 shares of Beta Bionics stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total transaction of $66,220.00. Following the completion of the transaction, the insider owned 80,752 shares in the company, valued at approximately $2,430,635.20. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Mike Mensinger also recently made the following trade(s):

• On Friday, January 2nd, Mike Mensinger sold 7,800 shares of Beta Bionics stock. The stock was sold at an average price of $29.61, for a total transaction of $230,958.00.
• On Tuesday, December 2nd, Mike Mensinger sold 1,063 shares of Beta Bionics stock. The shares were sold at an average price of $29.34, for a total transaction of $31,188.42.

Beta Bionics Stock Up 0.3%

Shares of Beta Bionics stock opened at $31.49 on Thursday. The firm has a market cap of $1.39 billion and a price-to-earnings ratio of -7.21. Beta Bionics, Inc. has a 52-week low of $8.89 and a 52-week high of $32.71. The company’s 50-day simple moving average is $29.32 and its 200-day simple moving average is $22.17.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Tuesday, October 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.12. The company had revenue of $27.25 million for the quarter, compared to analysts’ expectations of $23.92 million. Beta Bionics had a negative return on equity of 35.72% and a negative net margin of 87.89%.

Institutional Trading of Beta Bionics

Several institutional investors have recently made changes to their positions in BBNX. Eventide Asset Management LLC boosted its holdings in Beta Bionics by 0.5% in the third quarter. Eventide Asset Management LLC now owns 4,957,252 shares of the company’s stock valued at $98,500,000 after acquiring an additional 24,901 shares during the last quarter. Farallon Capital Management LLC increased its position in Beta Bionics by 2.6% during the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock worth $85,718,000 after purchasing an additional 110,000 shares in the last quarter. Soleus Capital Management L.P. raised its holdings in Beta Bionics by 12.5% in the second quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock valued at $55,622,000 after buying an additional 424,817 shares during the period. Sands Capital Alternatives LLC boosted its stake in shares of Beta Bionics by 15.0% in the second quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company’s stock valued at $51,981,000 after purchasing an additional 466,331 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Beta Bionics by 213.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock valued at $44,036,000 after purchasing an additional 1,509,217 shares in the last quarter.

Analyst Ratings Changes

Several research firms recently commented on BBNX. Wall Street Zen upgraded shares of Beta Bionics from a “strong sell” rating to a “hold” rating in a research report on Saturday, November 1st. Robert W. Baird set a $28.00 price target on shares of Beta Bionics in a report on Tuesday, December 16th. Truist Financial increased their price target on shares of Beta Bionics from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $31.00 target price (up previously from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $32.00 price objective (up previously from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Beta Bionics currently has an average rating of “Moderate Buy” and an average target price of $29.70.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.